Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay

Hybridoma

Volumn 18, Issue 6, 1999, Pages 535-541

  Wang, Tang J ^a   Linton, H Jay ^a   Payne, Janice ^a   Rittenhouse, Harry G ^a   Chan, Daniel W ^b   Partin, Alan W ^b   Wolfert, Robert L ^a   Kuus Reichel, Kristine ^a  

^a Hybritech Incorporated   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN G; CHYMOTRYPSIN INHIBITOR; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; CANCER IMMUNOLOGY; COMPLEX FORMATION; CROSS REACTION; HUMAN; HUMAN TISSUE; HYBRIDOMA; IMMUNOASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

ALPHA 1-ANTICHYMOTRYPSIN; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; AREA UNDER CURVE; CATHEPSINS; CROSS REACTIONS; HUMANS; HYBRIDOMAS; IMMUNOASSAY; MALE; MICE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; ROC CURVE; SERINE ENDOPEPTIDASES;

EID: 0033371616     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Stenman U-H, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, and Alfthan O: A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Can Res 1991;51:222-226.
2. Lilja H, Christensson A, Dahlen U, Matikainen M-T, Nilsson O, Pettersson K, and Lovgren T: Prostate-specific antigen in serum occurs predominantly in complex with al-antichymotrypsin. Clin Chem 1991;37:1618-1625.
3. Pettersson K, Piironen T, Seppala M, Liukkonen L, Christensson A, Matikainen M-T, Suonpaa M, Lovgren T, and Lilja H: Free and complexed prostate-specific antigen (PSA): In vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-α1-antichymotrypsin complex. Clin Chem 1995;41:1480-1488.
4. Chan DW, Kelley CA, Partin AW, Linton J, Wang TJ, Sokoloff RL, Rittenhouse HG, and Wolfert RL: PSA-ACT immunoassay: Problems and solutions. Clin Chem 1996;42:s255.
5. 2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 1991;30:1723-1730.
6. Salvesen G, and Enghild JJ: Proteinase inhibitors: An overview of their structure and possible function in the acute phase. In: Acute phase proteins: Molecular Biology, Biochemistry, and Clinical Applications. Mackiewicz A, Kushner I, Baumann H (Eds.). CRC Press, Boca Raton, FL, 1993, pp. 117-148.
7. Villoutreix BO, Lilja H, Pettersson K, Lovgren T, and Teleman O: Structural investigation of the alpha-1-antichymotrypsin: prostatespecific antigen complex by comparative model building. Protein Science 1996;5:836-851.
8. Heidtmann H-H, and Havemann K: Assay of complexed α1-antichymotrypsin in plasma. Clin Chem 1993;39:869-874.
9. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, and Chan DW: Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology 1996;48:55-61.
10. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, DeKernion JB, Walsh PC, Scardino PT, et al.: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 1998;279:1542-1547.
11. Prestigiacomo AF, Chichibu K, Kuroe K, and Stamey TA: Serum PSA assays should be based on PSA-ACT complex to improve the specificity for diagnosing benign prostatic hyperplasia (BPH). J Urol 1997;159(suppl.):366.
12. Zhang P, Wilson LW, and Wu JT: Measurement of free PSA: Assay characteristics and clinical applications. Clin Chem 1996;42:s265.
13. Bjork T, Piironen T, Pettersson K, Lovgren T, Stenman U-H, Oesterling JE, Abrahamsson P-A, and Lilja H: Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 1996;48:882-888.
14. Reiter W, Stieber P, Schmeller N, Nagel D, and Fateh-Mogahadam A: Alpha 1-antichymotrypsin-PSA (PSA-ACT): A useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate? Anticancer Res 1997;17:4767-4770.
15. 1 antichymotrypsinprostate-specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia. Clin Chem 1999;45:422-424.
16. Sokoll L, and Chan D: Total, free, and complexed PSA: Analysis and clinical utility. J Clin Ligand Assay 1998;21:171-179.
17. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, Wolfert RL, and Saedi MS: A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50:710-714.
18. Knott CL, Kuus-Reichel K, Liu RS, and Wolfert RL: Development of antibodies for diagnostic assays. In: Principles and Practice of Immunoassay. Price CP, Newman DJ (eds.). Stockton Press, New York 1997, pp. 37-64.
19. 1-antichymotrypsin complex for the screening and management of prostate cancer. J Clin Lab Anal 1998;12:32-40.
20. Wu JT, Zhang P, Liu GH, and Wilson L: Development of an immunoassay specific for the PSA-ACT complex without the problem of high background. J Clin Lab Anal 1998;12:14-19.
21. Allard WJ, Zhou Z, and Yeung KK: Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998;44:1216-1223.
22. Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK, and Allard WJ: Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998;52:372-378.
23. Sokoll LJ, Bruzek DJ, Cox JL, Partin AW, Chan DW, Morris DL, Yeung KK, and Allard WJ: Is complexed PSA alone clinically useful? J Urol 1998;159(suppl.):234.
24. Chen Z, Chen H, and Stamey TA: Monoclonal Antibodies 2F5 and 4G10 against prostate specific antigen (PSA) complexed to α1-antichymotrypsin. J Urol 1998;160:870-875.